{"id":"W4387811378","doi":"10.1016/j.annonc.2023.09.1927","title":"748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Institut Gustave-Roussy; Université Paris-Saclay; Seagen; Wilmot Cancer Institute, University of Rochester Medical Center; Università Cattolica del Sacro Cuore; Incyte; Clovis Oncology; PharmaMar; AstraZeneca","keywords":"Medicine; Lenvatinib; Pembrolizumab; Endometrial cancer; Oncology; Internal medicine; Gynecology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004469384,0.0002533563,0.0004683392,0.000263935,0.0003298737,0.0005581766,0.0002615394,0.0004624118,0.005547704],"category_scores_gemma":[0.001047941,0.000133105,0.002007924,0.0004610473,0.000138301,0.0006175849,0.0004090238,0.00126109,0.000638223],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006759034,"about_ca_system_score_gemma":0.0008558889,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003562562,"about_ca_topic_score_gemma":0.007097373,"domain_scores_codex":[0.9997812,0.00005232329,0.00001763628,0.00004634508,0.00003151668,0.00007108072],"domain_scores_gemma":[0.9994197,0.0001138022,0.0001973242,0.00003282123,0.00006389895,0.0001725405],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1059556,0.001780572,0.7641837,0.0008601642,0.003669395,0.00050534,0.0001479525,0.003261283,0.001931367,0.0007817642,0.02584781,0.09107502],"study_design_scores_gemma":[0.008685577,0.01918189,0.9531388,0.0001708335,0.002327614,0.0006010553,0.0003179769,0.002084021,0.0007287177,0.001142495,0.01157578,0.00004516237],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9595663,0.002008266,0.0003400215,0.0008717116,0.0002216455,0.0001841916,0.0275127,0.00002997892,0.009265133],"genre_scores_gemma":[0.9736352,0.0007497164,0.0002317749,0.0006173292,0.0001411001,0.0002303189,0.01842723,0.000008938509,0.005958243],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005547704,"threshold_uncertainty_score":0.01855892,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1202288141960582,"score_gpt":0.445605186139276,"score_spread":0.3253763719432178,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}